Newer modes of therapy for NIDDM.
Muralidharan
R
R
Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh-160012, India.
Dash
R J
RJ
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007334:Insulin-Like Growth Factor I / Q000627:therapeutic use; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*
D000318:Adrenergic beta-Agonists; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; D007334:Insulin-Like Growth Factor I